SNORD83B: A Small Nucleolar RNA in Focus (G116938)

Target Name: SNORD83B

NCBI ID: G116938

SNORD83B

Other Name(s): Small nucleolar RNA, C/D box 83B | RNU83B | U83B | small nucleolar RNA, C/D box 83B

SNORD83B: A Small Nucleolar RNA in Focus

Nucleolar RNA (NRNA) plays a critical role in the regulation of gene expression in eukaryotic cells. Among the various NRNAs, small nucleolar RNA (snRNA) is of particular interest due to its functions in regulating gene expression and cell development. One of the key functional SNORs is SNORD83B, which is a 24.1 kilobase (kb) RNA molecule. In this article, we will discuss the biology of SNORD83B, its potential drug targets, and its potential as a biomarker.

biological background

SNORD83B is a 24.1-kilometer-long ribonucleic acid (NRNA) that plays a key role in eukaryotic cells. SNORD83B plays an important role in gene expression and cell development, including regulating gene expression, chromatin structure, RNA binding, and nuclear sorting.

Biological functions of SNORD83B

The main way in which SNORD83B exerts its biological functions in eukaryotic cells is through binding to DNA and RNA-binding proteins. By binding to DNA, SNORD83B can affect the initiation of gene expression, including RNA polymerase binding and promoter enhancement. In addition, SNORD83B can also bind to RNA, including mRNA, rRNA and tRNA, thereby participating in the regulation of gene expression.

In addition, SNORD83B also plays an important role in chromatin structure. Chromatin structure is mainly composed of DNA and histones. SNORD83B can affect the morphology and structure of chromatin by binding to histones, thereby affecting gene expression.

Pharmacological significance of SNORD83B

SNORD83B is a potential drug target because it is an RNA-binding protein, and these proteins are often closely related to the onset and progression of disease. Many diseases, including cancer, neurodegenerative diseases, and immune dysregulation, are associated with abnormal expression and/or dysfunction of SNORD83B.

drug target

1. SNORD83B and cancer

Many cancers, including lung cancer, liver cancer, breast cancer, and ovarian cancer, are associated with abnormal expression and/or dysfunction of SNORD83B. Studies have shown that the expression level of SNORD83B is positively correlated with tumor invasion and metastasis. In addition, the expression level of SNORD83B is also related to the survival rate of tumor patients.

2. SNORD83B and neurodegenerative diseases

Neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are closely related to abnormal expression and/or dysfunction of SNORD83B. Studies have shown that the expression level of SNORD83B is highly correlated with neuronal damage and neuron death. In addition, SNORD83B expression levels are associated with the risk of clinical progression of neurodegenerative diseases.

3. SNORD83B and immune disorders

Immune dysregulation diseases, such as autoimmune diseases, inflammatory bowel disease, and systemic lupus erythematosus, are also associated with abnormal expression and/or dysfunction of SNORD83B. Studies have shown that the expression level of SNORD83B is highly correlated with immune cell dysfunction. In addition, the expression level of SNORD83B is also related to the risk of immune dysregulation diseases.

The biological function and pharmacological significance of SNORD83B make it a potential drug target. By inhibiting the biological functions of SNORD83B, many diseases can be treated, including cancer, neurodegenerative diseases, and immune disorders. Future research will focus on drug preclinical research and clinical trials of SNORD83B.

Protein Name: Small Nucleolar RNA, C/D Box 83B

The "SNORD83B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORD83B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets